Bone Biologics (BBLG) - 2024 Q4 - Annual Report
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-40899 Bone Biologics Corporation (Exact name of registrant as specified in its charter) Delaware 42-1743430 Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Indicate by check ...